NewsRx

Search our medical news database

AIDS-Related Non-Hodgkin Lymphoma

High-Dose Cytosine Arabinoside-Based Regimens Effective As Salvage Therapy

Published in AIDS Weekly, February 11th, 2002

by Michael Greer, senior medical writer - Researchers in California say that high-dose cytosine arabinoside (Ara-C)-based chemotherapy regimens can provide some hope for HIV patients with refractory or relapsed non-Hodgkin lymphoma.

"No effective salvage regimen has been defined for patients with AIDS-related non-Hodgkin's lymphoma (AIDS-NHL) who do not respond to first-line chemotherapy that contains anthracycline," according to Dr. Jia Bi and colleagues at the University of Southern California's Keck School of Medicine in Los Angeles.

Despite a high degree of toxicity, intensive Ara-C regimens can produce relatively high response rates, Bi and...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook